<DOC>
	<DOC>NCT01425190</DOC>
	<brief_summary>This is a study to determine the pharmacokinetics (PK) and weight-based dose of boceprevir following single oral dose administration in Chronic Hepatitis C Virus (HCV) pediatric participants.</brief_summary>
	<brief_title>Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Documented chronic hepatitis C (CHC) genotype 1 infection Treatment naïve or failed previous interferon/ribavirin therapy (≥12 uninterrupted weeks) Weigh between 10 kg to 90 kg inclusive at screening and baseline (Day 1). Body Mass Index (BMI) from the 5th to the 95th percentile for the participant's age and gender, inclusive, per tables from the Center for Disease Control and Prevention, USA Use of acceptable methods of contraception for at least 3 months prior to baseline and continue on study Coinfection with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive). Treatment with ribavirin within 90 days, or any interferonalfa within 30 days Discontinued from interferon treatment due to adverse events Currently receiving antiviral/immunomodulating therapy for hepatitis C Prior treatment with an HCV protease inhibitor Prior treatment with any known hepatotoxic agent (including herbal remedies) Use of investigational drugs within 30 days of enrollment into study Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy. Substance abuse (including but not limited to alcohol abuse, illicit drugs, inhalational drugs, marijuana use, etc) any time prior to entry into the study Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. Pregnant or breastfeeding female Meeting any of the laboratory exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>